New drug combo for advanced nasopharyngeal cancer after immunotherapy
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of two drugs, irinotecan liposome and S-1, for people with a type of nose and throat cancer that has spread or come back after treatment with immunotherapy (PD-1/L1 inhibitors). The goal is to see if this new combination can help when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer that has spread or come back after at least one round of immunotherapy.
- You are at least 18 years old.
- Your cancer cannot be removed with surgery or treated with radiation.
- You have at least one tumor that can be measured on a scan (CT scan).
- You are in relatively good health, able to care for yourself (ECOG score 0-1).
- Your liver, kidney, and blood cell counts are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of drugs for people whose nasopharyngeal cancer has stopped responding to standard treatments like platinum chemotherapy and PD-1 inhibitors. It aims to find a new effective approach for advanced or recurrent disease.
This trial tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) for nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this combination helps slow or shrink the cancer.
This trial tests a combination of a chemotherapy drug (mitoxantrone liposome) with an immunotherapy (PD-1 blocker) for people whose nasopharyngeal cancer has come back or spread and hasn't responded to previous treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new drug (BL-B01D1) given alone or with another drug that helps the immune system fight cancer (called a PD-1 inhibitor). It is for people with newly diagnosed, locally advanced nasopharyngeal cancer. The goal is to see if this combination can shrink or control the cancer better.
This study tests a new way to treat nasopharyngeal cancer that has spread, using a special type of radiation plus an immunotherapy drug. It is for people who cannot or choose not to have chemotherapy, and it aims to control the cancer while keeping side effects manageable.
This study tests two immunotherapy drugs together for people whose nasopharyngeal cancer has continued to grow after standard treatments. The goal is to see if this combination can help shrink or slow the cancer.
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.